Key result
Preprocedural cardiogenic shock linked to ~24-fold higher 30-day mortality in left main stem PCI.
Why the study?
Real-world data on outcomes and predictors of mortality following left main stem PCI remain limited.
What are the predictors of 30-day and 12-month mortality in patients undergoing left main stem percutaneous coronary intervention?
Cohort (n=484)
Yes
What are the predictors of 30-day and 12-month mortality in patients undergoing left main stem percutaneous coronary intervention?
Odds Ratio: 23.88 (95% CI 7.9–72.2)
In a contemporary real-world UK cohort, LMS-PCI carries a 12-month mortality of 16.7%, with outcomes strongly predicted by older age, ACS presentation, preexisting renal disease, and preprocedural cardiogenic shock.
Real-world LMS-PCI data remain limited; leaves open optimal patient selection and long-term outcomes versus CABG.
INTRODUCTION: Left main stem percutaneous coronary intervention (LMS-PCI) is a complex high-risk procedure which can be performed as an alternative to coronary artery bypass graft (CABG) procedure in surgical turn-down patients or where there is equipoise in percutaneous versus surgical strategies. Current guidelines suggest that PCI is an appropriate alternative to CABG in patients with unprotected LMS disease and low SYNTAX score. However, "real world" data on outcomes of LMS-PCI remain limited. This study aims to quantify and determine predictors of mortality following LMS-PCI. METHODS: Using local coronary angioplasty registries from two UK centers, all LMS-PCI cases were identified from 2016 to 2020. Descriptive statistics and multivariate logistic regressions were used to examine the association between baseline and procedural characteristics with 30-day and 12-month mortality. RESULTS: We identified 484 cases of LMS-PCI between 2016 and 2020. There was a year-on-year increase in the number of LMS-PCI, the highest being in 2020. Covariates associated with higher 30-day mortality were age (OR 1.07, 95% CI: 1.02-1.12) and shock preprocedure (OR 23.88, 95% CI: 7.90-72.20). Covariates associated with higher 12-month mortality were age (OR 1.04, 95% CI: 1.01-1.08), acute coronary syndrome (ACS) (OR 2.50, 95% CI: 1.08-5.80), renal disease (OR 5.24, 95% CI: 1.47-18.68), and shock preprocedure (OR 7.93, 95% CI: 3.30-19.05). Overall, 30-day and 12-month mortality in this contemporary data set were 9.5% and 16.7%, respectively, with significantly lower rates in elective cases (p < 0.01). CONCLUSIONS: Older age and cardiogenic shock preprocedure were associated with increased 30-day mortality after LMS-PCI. Twelve-month mortality was associated with older age, ACS presentation, preexisting renal disease, and cardiogenic shock preprocedure.
No takes yet. Share an insight, caveat, or question.
Carande et al. (2022) conducted a cohort in Left main stem disease (n=484). Cardiogenic shock preprocedure vs. No cardiogenic shock was evaluated on 30-day mortality (OR 23.88, 95% CI 7.90-72.20). In 484 cases of left main stem PCI, overall 30-day mortality was 9.5%, with preprocedural cardiogenic shock strongly predicting 30-day mortality (OR 23.88; 95% CI 7.90-72.20).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: